CCO Independent Conference Coverage of the 2023 ASCO Genitourinary Cancers Symposium *

Read an expert preview commentary, download Capsule Summary slidesets, and read an expert analysis text module highlighting key studies from the 2023 Genitourinary Cancers Symposium.

Share

Program Content

Activities

ASCO GU 2023: Key Studies
An Expert’s Guide to Key Studies at the 2023 ASCO Genitourinary Cancers Symposium
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: February 16, 2023

Expires: February 15, 2024

Activities

TALAPRO-2
TALAPRO-2: Phase III Trial of First-line Talazoparib + Enzalutamide in mCRPC
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 21, 2023

Expires: February 20, 2024

MAGNITUDE Update: Niraparib in mCRPC
MAGNITUDE: Update of Phase III Trial of First-line Niraparib With Abiraterone Acetate and Prednisone in mCRPC With HRR Gene Alterations
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 21, 2023

Expires: February 20, 2024

TRITON3: Rucaparib in mCRPC
TRITON3: Phase III Trial of Rucaparib vs Physician’s Choice Therapy in Metastatic CRPC With BRCA or ATM Alterations
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 21, 2023

Expires: February 20, 2024

ARASENS Post Hoc Analysis
ARASENS: Post Hoc Analysis of Outcomes by Disease Volume and Risk With Darolutamide vs Placebo in Combination With ADT + Docetaxel in Metastatic HSPC
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 22, 2023

Expires: February 21, 2024

PACE-A
PACE-A: Phase III Trial of Stereotactic Body Radiotherapy vs Surgery for Localized Prostate Cancer
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 24, 2023

Expires: February 23, 2024

Neoadjuvant Pembrolizumab + CT in MIUC
Phase Ib/II Study of Neoadjuvant Chemotherapy + Pembrolizumab for Muscle-Invasive Urothelial Cancer
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 22, 2023

Expires: February 21, 2024

JAVELIN Bladder 100
JAVELIN Bladder 100: Long-term Follow-up of Avelumab Maintenance for Advanced Urothelial Cancer by First-line Chemotherapy Regimen
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2023

Expires: February 26, 2024

TROPHY-U-01 Cohort 2
TROPHY-U-01 Cohort 2: Sacituzumab Govitecan After Checkpoint Inhibition in Platinum-Ineligible Metastatic Urothelial Cancer
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 22, 2023

Expires: February 21, 2024

CheckMate 9ER 3-Yr Follow-up
CheckMate 9ER: 3-Yr Follow-up of First-line Nivolumab + Cabozantinib vs Sunitinib in Advanced/Metastatic RCC
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 22, 2023

Expires: February 21, 2024

CaboPoint
CaboPoint: Phase II Trial of Second-line Cabozantinib Following Checkpoint Inhibitor–Based Combination Therapy for Advanced RCC
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 24, 2023

Expires: February 23, 2024

PROpel Final Prespecified OS Analysis
Final Prespecified OS Analysis of PROpel: Phase III Trial of First-line Abiraterone + Olaparib vs Abiraterone + Placebo in Metastatic CRPC
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 22, 2023

Expires: February 21, 2024

KEYNOTE-057 Cohort B
KEYNOTE-057 Cohort B: Phase II Trial of Pembrolizumab Monotherapy in Patients With High-Risk Papillary NMIBC
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 24, 2023

Expires: February 23, 2024

Activities

Expert Analysis: ASCO GU 2023
CCO Independent Conference Highlights of the 2023 ASCO Genitourinary Cancers Symposium
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: April 28, 2023

Expires: April 27, 2024

Faculty

cover img faculity

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology
Director, Prostate and GU Medical Oncology
Yale Cancer Center
New Haven, Connecticut

cover img faculity

Elizabeth R. Plimack, MD, MS, FASCO

Deputy Director
Professor of Medical Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.